Evoxac (cevimeline hydrochloride)

Where it stands

According to the official records, the US FDA approved Evoxac (cevimeline hydrochloride) on 2026-10-15. The sponsor is Cosette, and the application is NDA221183. The approval is recorded as a new dosage form, specifically a solution.

The records give no CHMP opinion date, which is expected for a US-only action because the CHMP is an EU body. They also do not list an indication or therapeutic area, so this analysis does not describe the clinical use of the new solution.

Regulatory pathway and designations

The only designation recorded is 'New dosage form'. In general, this means FDA approved a new presentation of an active ingredient, here a solution, under a New Drug Application. It does not by itself mean a new active ingredient or a new indication.

The records do not say which NDA route was used (for example a full application or one relying partly on existing data). They also do not say whether clinical or bioavailability data supported the filing, or whether there were expedited-review designations, orphan status, exclusivity grants or a PDUFA goal date. None of these should be inferred from the records.

The records list one milestone, the FDA approval on 2026-10-15, marked as an official source. No earlier submission or review milestones are provided.

Safety and pharmacovigilance

The records contain no safety information, such as label warnings, contraindications, risk management requirements or postmarketing commitments, so no safety assessment can be made from them.

What to watch

The key next step is to review the FDA-approved labeling and approval letter for NDA221183. They should confirm the indication, strength, dosing and administration for the solution, and any postmarketing requirements. Those documents are not part of the records provided.

For commercial and medical teams, the open questions are the launch timing and availability of the solution, how it relates to Evoxac's existing presentation, and any exclusivity attached to the approval. The records do not address any of these. Any assessment should wait for the label and company communications.